Oxeia Biopharmaceuticals

Oxeia Biopharmaceuticals is a company in the clinical testing phase within the biotechnology industry. They are focused on developing groundbreaking treatments for mild traumatic brain injury (mTBI), commonly known as concussion, and associated neuro-metabolic disorders. The organization is currently conducting a Phase 2 clinical trial for their drug, OXE-103, scheduled to commence in the autumn of 2020. Up to now, there have been limited research initiatives targeting the treatment of these patients. The U.S. Centers for Disease Control and Prevention suggests that just below three million cases of concussion seek medical attention in U.S. emergency departments each year. Alternative studies indicate a much higher figure of five million cases, with as many as 2.4 million involving mTBI.